[HTML][HTML] The adenosine A2A receptor antagonist/inverse agonist, KW-6356 enhances the anti-parkinsonian activity of L-DOPA with a low risk of dyskinesia in MPTP …
Y Ohno, E Okita, M Kawai-Uchida, Y Shoukei… - Journal of …, 2023 - Elsevier
The adenosine A 2A receptor antagonist/inverse agonist, KW-6356 has been shown to be
effective in Parkinson's disease (PD) patients as monotherapy and as an adjunct therapy to …
effective in Parkinson's disease (PD) patients as monotherapy and as an adjunct therapy to …
The adenosine A2A receptor antagonist/inverse agonist, KW-6356 enhances the anti-parkinsonian activity of L-DOPA with a low risk of dyskinesia in MPTP-treated …
Y Ohno, E Okita, M Kawai-Uchida… - Journal of …, 2023 - pubmed.ncbi.nlm.nih.gov
The adenosine A 2A receptor antagonist/inverse agonist, KW-6356 has been shown to be
effective in Parkinson's disease (PD) patients as monotherapy and as an adjunct therapy to …
effective in Parkinson's disease (PD) patients as monotherapy and as an adjunct therapy to …